Yin H J
Department of Pediatrics, People's Hospital, Beijing Medical University.
Zhonghua Yi Xue Za Zhi. 1992 Oct;72(10):608-11, 639-40.
BALB/C mice (H-2d) receiving allogeneic C57 mice (H-2b) spleen cells via the portal vein (PV), followed by administration of cyclophosphamide (CY), abrogated the capability of rejecting allogeneic EL-4G- tumor cells (C57 origin). BALB/C mice received this combined treatment and BALB/C mice untreated or treated with either PV presensitization or CY injection were all exposed to 7.5 Gy total body irradiation, which was confirmed to be a lethal dose for BALB/C mice, then given intravenously 2 x 10(7) fetal liver cells from C57 mice (FLC57). The results indicated that the survival times of grafted BALB/C mice combined treatment were longer than those of untreated or either PV or CY treated, (PV + CY + 7.5Gy + FLC 57: MST = 99.5 +/- 12.6 day), v(N + 7.5GY + FLC57: MST = 36.5 +/- 9.8 day; PV + 7.5Gy + FLC57: MST = 12.2 +/- 0.2 day; CY + 7.5Gy + FLC57: MST = 27.6 +/- 5.5 day). The difference was statistically significant. The spleen cells from the grafted mice were assessed by indirect immunofluorescence with anti-C57 serum. The spleen cells from BALB/C mice with survival time over 100 days after grafting of FLC57 in combined treatment group were about 70-80 percentage of C57 positive cells.
通过门静脉(PV)接受同种异体C57小鼠(H-2b)脾细胞的BALB/C小鼠(H-2d),随后给予环磷酰胺(CY),消除了排斥同种异体EL-4G-肿瘤细胞(C57来源)的能力。接受这种联合治疗的BALB/C小鼠以及未治疗或仅接受PV预致敏或CY注射治疗的BALB/C小鼠均接受7.5 Gy全身照射,已证实这对BALB/C小鼠是致死剂量,然后静脉注射2×10⁷个来自C57小鼠的胎肝细胞(FLC57)。结果表明,联合治疗的移植BALB/C小鼠的存活时间比未治疗或仅接受PV或CY治疗的小鼠更长,(PV + CY + 7.5Gy + FLC 57:平均存活时间(MST)= 99.5±12.6天),相比(未治疗+ 7.5GY + FLC57:MST = 36.5±9.8天;PV + 7.5Gy + FLC57:MST = 12.2±0.2天;CY + 7.5Gy + FLC57:MST = 27.6±5.5天)。差异具有统计学意义。用抗C57血清通过间接免疫荧光评估移植小鼠的脾细胞。联合治疗组在移植FLC57后存活时间超过100天的BALB/C小鼠的脾细胞中,约70 - 80%为C57阳性细胞。